Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 22;1(6):e000144.
doi: 10.1136/esmoopen-2016-000144. eCollection 2016.

Hallmarks of glioblastoma: a systematic review

Dorte Schou Nørøxe  1 , Hans Skovgaard Poulsen  2 , Ulrik Lassen  2
Affiliations

Hallmarks of glioblastoma: a systematic review

Dorte Schou Nørøxe et al. ESMO Open. .

Abstract

Despite decades of intense research, the complex biology of glioblastoma (GBM) is not completely understood. Progression-free survival and overall survival have remained unchanged since the implementation of the STUPP regimen in 2005 with concomitant radio-/chemotherapy and adjuvant chemotherapy with temozolomide. In the context of Hanahan and Weinberg's six hallmarks and two emerging hallmarks of cancer, we discuss up-to-date status and recent research in the biology of GBM. We discuss the clinical impact of the research results with the most promising being in the hallmarks 'enabling replicative immortality', 'inducing angiogenesis', 'reprogramming cellular energetics' and 'evading immune destruction'. This includes the importance of molecular diagnostics according to the new WHO classification and how next generation sequencing is being implemented in the clinical daily life. Molecular results linked together with clinical outcome have revealed the importance of the prognostic biomarker isocitratedehydrogenase (IDH), which is now part of the diagnostic criteria in brain tumours. IDH is discussed in the context of the hallmark 'reprogramming cellular energetics'. O-6-methylguanine-DNA methyltransferase status predicts a more favourable response to treatment and is thus a predictive marker. Based on genomic aberrations, Verhaak et al have suggested a division of GBM into three subgroups, namely, proneural, classical and mesenchymal, which could be meaningful in the clinic and could help guide and differentiate treatment decisions according to the specific subgroup. The information achieved will develop and improve precision medicine in the future.

Keywords: Glioblastoma WHO classification Hallmarks of cancer Precision medicine Three subgroups; classical; mesenchymal; proneural.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Top 20 mutated genes in glioblastoma based on 712 samples of astrocytoma grade IV. 16
Figure 2
Figure 2
The intrinsic apoptotic pathway is a balance between proapoptotic proteins, for example, Bax and Bak and antiapoptotic proteins. The latter works by inhibiting Bax and Bak. When the inhibition stops, Bax and Bak change the mitochondrial outer membrane, causing release of cytochrome C, which triggers the Caspases and causes apoptosis.
See this image and copyright information in PMC

References

    1. Ostrom QT, Gittleman H, Fulop J, et al. . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015;17(suppl 4):iv1–iv62.10.1093/neuonc/nov189 - DOI - PMC - PubMed
    1. Louis DN, Perry A, Reifenberger G, et al. . The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–20.10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Stupp R, Hegi ME, Mason WP, et al. ; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.10.1016/S1470-2045(09)70025-7 - DOI - PubMed
    1. Michaelsen SR, Christensen IJ, Grunnet K, et al. . Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer 2013;13:402.10.1186/1471-2407-13-402 - DOI - PMC - PubMed
    1. Verhaak RG, Hoadley KA, Purdom E, et al. ; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98–110.10.1016/j.ccr.2009.12.020 - DOI - PMC - PubMed

LinkOut - more resources